Indegene Limited · NSE:INDGN
Indegene — Q1 FY2025 Earnings Presentation
21 slides from Indegene's earnings presentation, Aug 1, 2024
Slide 1: Exchange filing cover letter
INDGN/SE/2024-25/24 August 1, 2024 BSE Limited, National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1, Block G, Dalal Street, Bandra Kurla Complex, Bandra (E), Mumbai- 400001, India. Mumbai – 400 051, India. Scrip Code: 544172 Trading symbol: INDGN Dear Sir / Madam,
Slide 2: Investor Presentation June 2024
Investor Presentation June 2024
Slide 3: Disclaimer
Disclaimer This presentation may include opinions and assumptions about future performance which could be considered as forward-looking statements. Forward-looking statements intrinsically cover several risks and uncertainties, which may lead to a material difference between actual results and the s
Slide 4: We operate at the intersection of healthcare and technology
We operate at the intersection of healthcare and technology Healthcare Tech-Led Delivery and Expertise Digital Capabilities Healthcare market understanding Digital-first approach In-depth domain knowledge Gen AI based tools and platform Navigating regulatory landscape Drive transformation Medical co
Slide 5: We are a Digital First Commercialization Partner
We are a Digital First Commercialization Partner We Provide Capabilities and Expertise Across the Commercialization Value Chain Regulatory and R&D / Clinical and Marketing and Sales Pharmacovigilance Medical Affairs Others Digital content Brand Strategy and Pharmacovigilance Medical content Patient
Slide 6: Our large addressable market is underpinned by growing outsourcing and rapid digital adoption
Our large addressable market is underpinned by growing outsourcing and rapid digital adoption Outsourcing and Tech Lifesciences at Inflection We Offer Solutions Large Market Opportunity Expanding our TAM Point Across Life Sciences End Markets Life Sciences Operations Spend Across Verticals ($B) ~9-1
Slide 7: Management Commentary on Q1FY25 results
Management Commentary on Q1FY25 results Manish Gupta, Chairman and Chief Executive Officer – “In Q1FY25, we achieved revenue growth of 11.4% and robust EBITDA growth of 14.5% vs Q1FY24. We continue to see momentum and growth with our largest client and a few of our Top 20 clients with increased acti
Slide 8: Q1 FY25: Business Highlights
Q1 FY25: Business Highlights INR 6,765 Mn 11.4% 9.7% Significant YoY revenue growth in YoY revenue growth in Revenue from Operations growth at scale INR terms USD terms 65 36 68% Strong client Active Client Relationships Clients with $1 Million+ Revenue from Top 20 relationships Revenue Global Bioph
Slide 9: Q1 FY25: Quarter Performance
Q1 FY25: Quarter Performance Amount in INR Mn Particulars Q1 FY25 Q1 FY24 YoY % FY24 FY23 YoY % Revenue from Operations 6,765 6,075 11.4% 25,896 23,061 12.3% Enterprise Medical Solutions 1,889 1,410 33.9% 6,008 5,602 7.3% Enterprise Commercial Solutions 3,750 3,672 2.1% 15,287 13,569 12.7% Omnichann
Slide 10: Long-standing and highly sticky client relationships
Long-standing and highly sticky client relationships 65 21 20 of Top 20 68% Active clients(1) Active clients (1) added Global biopharma Revenue from top 20 global FY2021 to Q1FY25 companies as clients (2) biopharma companies(2) Successful track record of growing accounts(4) # Growing active client b
Slide 11: Business mix
Business mix Revenue from Service offering ($Mn) Revenue by Customer Industry (%) Revenue by Customer Geography (%) 73.9 81.1 81.1 3% 2% 3% 1% 1% 5% 5% 4% 11% 13% 12% 32% Q1FY25 Q1FY25 60% 58% 55% 65% 93% 23% 24% 28% Q1FY24 Q4FY24 Q1FY25 Enterprise Medical Solutions Enterprise Commercial Solutions B
Slide 12: Financial Highlights
Financial Highlights © 2024 Indegene. All rights reserved. 11
Slide 13: Q1 FY25 Consolidated Financials
Q1 FY25 Consolidated Financials Amount in INR Mn Particulars Q1 FY25 Q4 FY24 Q1 FY24 QoQ % YoY % FY24 FY23 YoY % Revenue from Operations 6,765 6,730 6,075 0.5% 11.4% 25,896 23,061 12.3% Employee Benefit Expenses 4,443 4,284 4,047 3.7% 9.8% 16,516 14,648 12.8% Other Expenses 1,033 1,059 1,060 -2.5% -
Slide 14: Healthy margin profile and robust balance sheet
Healthy margin profile and robust balance sheet EBITDA and EBITDA Margin(1) PAT and PAT Margin Cash and Cash Equivalent(2) INR Mn and % INR Mn and % INR Mn 21.9% 14.1% 19.6% 13.0% 19.1% 11.3% 13,973 1,474 948 1,328 877 1,160 9,876 684 7,300 Q1FY24 Q4FY24 Q1FY25 Q1FY24 Q4FY24 Q1FY25 Q1FY24 Q4FY24 Q1F
Slide 15: Awards and Recognitions
Awards and Recognitions AIM Data Breakthrough Awards, 2024: Data AIM 50 Best Firms for Data Scientists to Work For 2024 Warehouse Solution of the Year Fierce Pharma Marketing Awards 2024: Professional Marketing AIM Data Engineering Awards, 2024: Data ET HRWorld Future Skills Awards, 2024: Technology
Slide 16: We are recognized as a domain expert and a thought leader
We are recognized as a domain expert and a thought leader Function-level industry councils We are recognized as a Annual Indegene 21.9% thought leader in Digital Summit Digital Council Emerging Biotech CEO Council Domain Expertise Headcount(1)(2) healthcare industry Regulatory Affairs Digital Medica
Slide 17: Annexure
Annexure © 2024 Indegene. All rights reserved. 16
Slide 18: We have grown our business through a land-and-expand strategy
We have grown our business through a land-and-expand strategy Revenue growth from our top 10 clients USD Million 42 25 24% 99% CAGR(1) CAGR(1) 35 35 20 32 32 29 17 17 15 14 22 13 20 19 12 11 11 10 14 9 9 13 5 4 4 4 2 1 1 1 0 Client 1 Client 2 Client 3 Client 4 Client 5 Client 6 Client 7 Client 8 Cli
Slide 19: Thank you
Thank you indegene’
Slide 20: Fact Sheet: Operational & Financial Metrics
Fact Sheet Consolidated Financial Data - First Quarter, Fiscal 2025 Operational & Financial Metrics Key performance indicators (in INR Mn) Quarter ended Growth SI. Particulars June 30, Mar 31, June 30, No. YoY QoQ 2024 2024 2023 1. Active clients(1)(No.) 65 63 63 2. Revenue from operations 6,765 6,7
Slide 21: Fact Sheet: Revenue by industry, clients and employees
Fact Sheet Consolidated Financial Data - First Quarter, Fiscal 2025 Revenue by customer industry (in %) Quarter ended (contribution) Growth Particulars June 30, Mar 31, June 30, YoY QoQ 2024 2024 2023 Biopharma 93.5 93.8 92.8 12.1 0.2 Medical Devices 2.7 2.8 3.7 -18.3 -2.6 Emerging Biotech 2.6 2.7 2